The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.

Clicks: 283
ID: 103142
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
Reference Key
caly2020theantiviral Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Caly, Leon;Druce, Julian D;Catton, Mike G;Jans, David A;Wagstaff, Kylie M;
Journal Antiviral research
Year 2020
DOI
S0166-3542(20)30201-1
URL
Keywords
china spatial analysis spatial autocorrelation covid-19

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.